UBS Group’s SpringWorks Therapeutics SWTX Stock Holding History

UBS Group’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,000	Closed	-$1.1M	–	10809
2025 Q1	$1.1M	Buy	+25,000	New	+$1.15M	﹤0.01%	5198

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's SWTX Position: Q3 2025 in Review

UBS Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 392,884 shares — an estimated $18.5M sold.

UBS Group first reported a position in SWTX in Q3 2019 and held it in 23 quarters. The position peaked at $27.6M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

UBS Group reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS Group sold 392,884 SpringWorks Therapeutics shares in Q3 2025, an estimated $18.5M.
UBS Group first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 23 quarters.
UBS Group's SpringWorks Therapeutics position peaked at $27.6M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.